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ABSTRACT
Objectives: To determine the prevalence, clinical features, risk factors and outcomes 
associated with cryptococcal meningitis (CM) in human immunodeficiency virus (HIV) 
positive patients at two referral hospitals in Nairobi, Kenya.
Design: Prospective, observational study.
Setting: Kenyatta National Hospital (KNH) and Mbagathi District Hospital (MDH), 
Nairobi, Kenya
Subjects: Three hundred and forty HIV patients presenting with suspected CM. 
Results: Of three hundred and forty suspected CM patients, 111 (33%) were diagnosed 
with CM by CrAg. Among CM patients, in-hospital mortality was 36% (38/106), median 
age was 35 years (range, 19-60 years) and median CD4 count was 41 cells/μL (n=89, range 
2-720 cells/μL). Common clinical manifestations among CM patients included headache 
103 (93%), neck stiffness 76 (69%) and weight loss 53 (48%). Factors independently 
associated with CM were male sex, headache, blurred vision and previous antifungal 
drug use. Night sweats and current use of anti-retroviral therapy were associated with 
reduced risk for CM. 
Conclusions: There is a high prevalence of CM and CM-associated mortality in HIV 
patients at KNH and MDH despite treatment with antifungal and anti-retroviral 
drugs. This study demonstrates the need to address the existing inadequacies of CM 
patient outcomes in Kenya. 
INTRODUCTION
The human immunodeficiency virus (HIV) epidemic 
continues to be a major challenge in Kenya. There 
are 1.4 million people infected with HIV in Kenya 
and the prevalence of HIV among adults aged 15-
49 years is currently estimated at 7.8% (1, 2). As a 
consequence of this epidemic, the opportunistic 
infection cryptococcal meningitis (CM) has become 
a leading cause of morbidity and mortality. Recent 
estimates from observational studies in Africa report 
mortality in CM patients ranging from 17% to 100% 
(3-8). Moreover, Africa has the highest burden of 
CM, with countries such as Rwanda, Democratic 
Republic of Congo, South Africa, Uganda, Kenya 
and Zimbabwe reporting double digit figures (4, 5, 
9-12). CM is becoming a more important cause of 
meningitis in HIV patients compared to bacterial 
and viral meningitis (5).
 There are few studies on CM among HIV patients 
in Kenya (4, 15, 16).  Problems with management of CM 
in hospitals in Kenya, as in many resource constrained 
settings, are compounded by over crowding, lack 
of essential equipment such as lumbar puncture 
(LP) needles, shortage of trained health providers 
and difficulties in obtaining antifungal therapies 
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(5, 6). Amphotericin B (AMB) is the drug of choice 
for treatment of CM (13, 14). Current guidelines for 
treatment of AIDS-associated CM for sub-Saharan 
Africa recommend 1 mg/kg/d AMB for two weeks 
as induction therapy or, if unavailable, FLC 800 mg 
for four weeks (14). However, the widespread use of 
AMB in Kenya has been limited by nephrotoxicity 
and cost (15). 
 The aim of this study was to define the burden, 
clinical features, risk factors and outcome associated 
with CM in HIV positive patients presenting with 
suspected meningitis at two referral hospitals in 
Kenya. We sought to conduct this study because of 
the need to understand the epidemiology of CM, an 
important tool in planning for the management of 
the disease (12). 
MATERIALS AND METHODS
Study design: We conducted a prospective, observational 
study in HIV patients with suspected CM at KNH 
and MDH in Nairobi, Kenya. Patients were recruited 
from the admitting wards between August 2008 and 
February 2009. 
Study settings and Participants: KNH is a large referral 
and teaching hospital in Kenya with 1,800 bed 
capacity. It serves as the primary hospital for the 
four million residents of the capital city of Nairobi. 
MDH is a 169-bed public hospital that serves as 
the Tuberculosis Referral Centre for Nairobi. Study 
participants were recruited from both hospitals. The 
following inclusion criteria were used:  (i) patient is 
an adult male or female aged 17 years and older; (ii) 
patient’s underlying immunosuppression is HIV 
infection; (iii) patient is suspected to have CM based 
on physician’s diagnosis using clinical symptoms. 
Suspected CM was defined as: (i) signs of meningeal 
irritation such as photophobia, neck rigidity, vomiting, 
and headaches; (ii) fever with altered mental state; 
(iii) unexplained change in mental state, or headache 
(5). Patients who had one or more of these symptoms 
were suspected to have CM. This definition was used 
by the admitting physicians at the two hospitals as 
the basis for recommending a lumbar puncture for 
confirmatory laboratory testing for CM. The exclusion 
criteria were: (i) Children; (ii) pregnant mothers; (iii) 
HIV negative patients even if their diagnosis indicated 
suspected CM.
  Ethical approval and permission for this 
study were obtained from the UAB Institutional 
Review Board and the Kenyatta National Hospital 
and University of Nairobi Research and Ethics 
Committee.   
Patient data collection: A structured questionnaire 
was administered to each enrolled patient. Data 
including demographic characteristics, duration 
of illness, symptoms and signs on admission, prior 
use of antifungal drugs (defined as antifungal drug 
consisting of AMB, FLC and clotrimazole, used any 
time prior to the current  admission), anti-retroviral 
therapy (ART) status, FLC treatment and clinical 
status of HIV infection were collected.  Patient medical 
records were also used retrospectively to obtain 
information such as date of HIV diagnosis, CD4 counts, 
HIV viral load, previous illnesses and treatments. 
We also recorded information on CM management 
including; antifungal drugs used, therapeutic lumbar 
puncture (LP), fundoscopy, computed tomography 
(CT) scan, creatinine measurements and monitoring, 
and opening pressure measurements. 
 In-hospital mortality was obtained from the 
admission registry and confirmed using patient 
clinical records. At the time of discharge, patients 
were referred to the KNH Comprehensive Care 
Center (CCC) where they were started on oral FLC. 
Patients were followed monthly for three months 
after discharge to assess treatment outcomes. 
Laboratory tests: Laboratory determination of 
cryptococcal infection was done at the University 
of Nairobi microbiology laboratory using CSF. 
Lumbar puncture (LP) was performed as part of the 
standard management of suspected CM cases.  All 
suspected CM patients had the LP performed before 
initiation of antifungal treatment. Five milliliters of 
CSF was obtained and stored at 2oC -8oC in sterile 
10 ml glass vials. CSF samples were tested using the 
Cryptococcal Antigen (CrAg) Latex agglutination 
test (Latex-Crypto test, Immuno-Mycologics, 
Norman, Oklahoma USA). Patients whose CSF 
tested positive for CrAg were considered to have 
CM. CSF was cultured on Sabouraud’s dextrose agar 
(SDA) to obtain cryptococcus isolates. To rule out 
contamination the presence of Cryptococcus species 
was confirmed by a positive urease test and the ability 
to grow at 37oC. The isolates were then transferred 
into SDA slants and stored at room temperature or 
aliquoted in glycerin and milk solution and stored 
at -80 oC. Isolates were shipped by air to the division 
of  laboratory machine, department of pathology 
at the University of Alabama at Birmingham for 
antifungal susceptibility testing and confirmation 
of identification. Antifungal susceptibility testing 
was performed by broth micro dilution method as 
outlined in the Clinical and Laboratory Standards 
Institute (CLSI) document M27-A3 (17) using FLC 
and AMB. Interpretive criteria for FLC (susceptible, 
MIC [minimum inhibitory concentration] ≤8 µg/ 
ml, susceptible dose dependent, MIC 16–32 µg/ ml 
and resistant, MIC ≥64 µg /ml) and AMB (resistant, 
MIC ≥2) was based on the study by Nguyen and Yu 
(18).
Clinical management of CM patients: The daily rate of 
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patient admission was approximately 30-40 at KNH 
and 10-15 at MDH. All consenting new patients 
admitted in the wards were tested for HIV as part 
of the standard of care irrespective of their previous 
HIV diagnosis. All patients received voluntary 
counselling and testing at the hospitals before and 
after HIV testing. All ART naïve patients were referred 
to start ART. The treatment protocol for CM differed 
in the two hospitals.  At KNH, patients with CM were 
treated with AMB (50 mg or 35 mg) for 14 days and 
then given FLC (400 mg or 200 mg) orally for eight 
weeks followed by FLC 200 mg until CD4 counts 
were >200 cell/µL. At MDH, AMB (only available 
to patients who could afford it) was escalated in 
dose: 12.5 mg on the first day, 25 mg on the second 
day and 35 mg for each of the next 12 days. FLC 800 
mg was then given daily for two weeks, followed by 
maintenance treatment with FLC 400 mg. Information 
on therapeutic LP and measurement of opening 
pressure was not available as these procedures were 
not done routinely. 
Data analysis: Categorical variables are represented 
as frequencies and percentages, and continuous 
variables as medians (range). The comparisons were 
performed using Chi-square test for categorical data 
and student’s t-test for continuous data. Correlation 
analyses were performed to detect multicollinearity 
between independent variables. A multivariable 
logistic regression analyses using a significance level 
of <0.05 was used to determine risk factors associated 
with CM. Variables that were statistically significant 
at p<0.05 on the bivariate model and those known 
to be associated with CM in HIV patients based on 
previous studies were entered into the multivariable 
model using the stepwise method. Odds ratios (OR) 
and 95% confidence intervals (CI) were generated as 
measures of association for all variables entered into 
the model. Observations with more than 10% missing 
values were excluded from the analysis. Data analysis 
was conducted using SAS, version 9.1 (SAS Institute 
Inc., Cary, North Carolina, USA).
RESULTS
Patient demographic characteristics: Of the 340 HIV 
positive patients with suspected CM who were 
enrolled into the study, 111 (33%) had laboratory 
confirmed CM.  Most patients were young males 
with secondary education or vocational training 
and were hospitalised for the first time with clinical 
suspicion of CM (Table 1). Positive CSF detection 
of Cryptococcus species in CM positive patients by 
CrAg and culture were 111/111 (100%) and 86/111 
(77%) respectively. 
Clinical features: Common clinical manifestations 
among patients with CM were; headache, neck 
stiffness and weight loss (Table 1). CM-related clinical 
features that were significantly more common among 
CM patients compared to the CM negative patients 
were headache (p<0.001) and blurred vision (p<0.001). 
Prior use of antifungal drugs was significantly 
higher in CM patients compared to patients without 
CM (p<0.001). Tuberculosis infection was the most 
common concurrent morbidity among CM positive 
patients.  
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Table 1
Characteristics of HIV positive patients with suspected CM at KNH and MDH, August 2008 - February 2009. 
Characteristic Total N=340 (%) CM Positive CM Negative P
   n=111(%) n=229 (%) Value
Sex 
 Male 162 (47.5) 64 (57.7) 98 (43.0) 0.01
 Female 178 (52.5) 47 (42.3) 131 (57.0)
Age (in years) 
 Median (Range) 35 (17-65) 35 (19-60) 35 (17-65) 1.0
Education 
 Primary 168 (49.1) 52 (46.0) 116 (51.1) 0.39
 Secondary/Vocational 172 (50.9) 59 (54.0) 113 (48.9)
On Antiretroviral drugs
 Yes 104 (30.6) 33 (29.7) 71 (31.0) 0.81
 No 236 (69.4) 78 (70.3) 158 (69.0)
Prior use of antifungal
drugs
 Yes 101 (29.7) 48 (43.2) 38 (16.6) <0.01
 No 239 (70.3) 63 (56.8) 191 (83.4)
First time hospitalization* 
 Yes 319 (93.8) 99 (89.2) 220 (96.1) 0.01
 No   21 (6.2) 12 (10.8) 9 (3.9)
Clinical outcomes
 Discharged alive 221 (65.0) 68/106 (64.0) 139/211 (66.0) <0.78
 In-hospital mortality 119 (35.0) 38/106 (36.0) 72/211 (34.0)
CD4 cell count (cells/ µL)
 <100 153/269 (57.0) 66/88 (75.0) 87/181 (48.1) <0.01
 100-200 46/269 (17.0) 11/88 (12.5) 35/181 (19.3)
 >200 70/269 (26.0) 41 (2-720) 104 (1-1089) <0.01
CD4 cell count (cells/ µL) 
 Median (Range) 72 (1-1089) 41 (2-720) 104 (1-1089) <0.01
Viral load (RNA levels,
Copies/ML) 
 <100,000 82/177 (46.3) 18/55 (32.7) 64/122 (53.0) 0.01
 >100,000 95/177 (53.7) 37/55 (67.3) 57/122 (47.0)
Viral load (RNA levels, 
Copies/ML) 
Median (Range)  164,000 (<40-10 376,000 (<40-6  49,000 (<40-10 <0.01
  million)  million)  million)
Concurrent morbidity
 Tuberculosis 111/191 (74.5) 45/56 (80.4) 66/93 (71.0) 0.32
 Malaria 17/191 (11.4) 4/56 (7.1) 13/93 (14.0)
 Pneumonia 10/191 (6.7) 2/56 (3.6) 8/93 (8.6)
 Other+ 11/191 (7.4) 5/56 (8.9) 6/93 (6.5)
Time to Discharge
 Median Days (Range)  14 (0-90) 19 (0-90) 11 (1-50) <0.01
Time to Death 
 Median Days (Range)  8 (2-73) 8 (2-73) 8 (2-33) 1.0
Signs and symptoms at
presentation
 Headache  274 (80.6) 103 (92.8) 171 (74.7) <0.0001
 Coughs  161 (47.4) 42 (38.0) 119 (52.0) 0.01
 Night sweats  121 (35.6) 25 (22.5) 96 (41.9) 0.0005
 Blurred vision  74 (21.8) 39 (35.1) 35 (15.3) <0.0001
 Neck stiffness  211 (62.1) 76 (68.5) 135 (59.0) 0.09
 Altered mental status  178 (52.4) 50 (45.1) 128 (55.9) 0.06
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Values in bold are statistically significant at p<0.05
Chi square was used for categorical data and student t-test for continuous variables.
CM = Cryptococcal meningitis
KNH = Kenyatta National Hospital 
MDH = Mbagathi District Hospital
Denominators included to show missing values
*First time hospitalisation for suspected CM 
+Other concurrent morbidities were herpes, diabetes, hypertension and osteoarthritis.
Laboratory Findings: The median CD4 lymphocyte 
counts for confirmed CM cases whose CD4 test 
results were available was 41 cells/µL (n=89, range 
2-720 cells/µL).  There was a significant difference 
in CD4 counts between patients with CM compared 
to those without (p<0.001). The median viral load 
among CM cases was 376,000 RNA copies/ML (n=55, 
range <40-6,000,000 RNA copies/ML). There was 
significant difference in viral load counts between CM 
positive patients and CM negative patients (p=0.01) 
(Table 1). Interestingly we found that all (67) C. gatti 
isolates from these patients were susceptible to both 
FLC (median MIC =  4.0, range 0.25-16.0 µg/ml) and 
AMB (median MIC = 1.0, range 0.5-1.0 µg/ml).
Risk factors for CM:  Our multivariable logistic 
regression results show that male sex (OR=2.3, CI 1.3-
3.9, p=0.003), headache (OR= 3.7, CI 1.6-8.6, p=0.002), 
blurred vision (OR= 2.3, CI 1.3-4.3, p=0.007) and prior 
antifungal drug use (OR=5.9, CI 3.3-10.3, p<0.0001) 
were independently associated with increased risk 
of having CM. Night sweats (OR= 0.4, CI 0.2-0.8, 
p=0.005) and being on anti-retroviral therapy at the 
time of admission (OR= 0.5, CI 0.2-1.0, p=0.04) were 
associated with reduced risk for CM.  
Patient Outcomes: In-hospital mortality among CM 
patients was 36% (Table 1). In-hospital mortality was 
not significantly higher in CM cases when compared 
to non-CM cases.  Most of the CM patients 52/68 
(76%) were lost to follow-up after discharge from 
hospital. The remaining 16 CM patients who were 
followed at the CCC were all alive after three months 
of follow up. 
DISCUSSION
Our results provide a rare description of the 
epidemiology of CM in HIV patients presenting with 
suspected CM at public hospitals in Kenya. We are 
reporting a CM prevalence of 33% and in-hospital 
mortality of 36% in HIV patients presenting with 
suspected CM at KNH and MDH. These results 
show the need to address the existing gaps in the 
management of this disease in Kenya.
 The CM prevalence in this study was higher 
than what is reported in a similar study by Jowi et al 
(4). We suspect these results over-estimated the true 
prevalence of CM in the general population. The 
study population consisted of patients who presented 
with signs of meningitis. These patients were more 
likely to have CM compared to the general hospital 
population.   Higher CM prevalence in this study may 
also be attributed to the characteristics of patients 
admitted to KNH and MDH.  Majority of the patients 
in this study live in the surrounding low income 
neighbourhoods and slums, typical characteristics 
of patients presenting with CM in Africa (3, 11). 
 Clinical presentation of CM patients in this study 
was similar to those reported in other studies (3, 5). 
Majority of our patients presented with headaches, 
neck stiffness and weight loss. Headache, blurred 
vision and a history of antifungal drug use predicted 
CM in this study. These predictors can be useful for 
early disease detection and timely management of 
CM in resource constrained settings like Kenya (3, 5). 
Night sweats and current use of ART were associated 
with reduced risk for CM. Based on these results; 
increasing access to ART to HIV patients can reduce 
the incidence of CM.  
 Mortality was high in our cohort despite the 
use of either FLC or AMB therapy, both of which 
were highly efficacious against all our isolates. We 
suspect that late presentation of patients contributed 
greatly to high CM-associated mortality in our 
study (3). Late presentation is evidenced by our 
finding that a large proportion (48%) of the CM 
patients showed signs of weight loss on admission 
and had a high level of immunosuppression. These 
patients had low CD4 counts and high viral loads 
at presentation. Renal toxicity associated with AMB 
may also have contributed to poor patient outcomes. 
A study by Ochieng et al reported a high incidence of 
nephrotoxicity among CM patients receiving AMB 
at KNH (15). 
 High CM-associated mortality rate in this 
study warrants an evaluation of the current CM 
management guidelines at the two hospitals. Despite 
its toxicity, AMB should continue to be the drug of 
choice for treatment of CM in Kenya. AMB clears 
cryptococcal infections more rapidly than FLC (19-
21). AMB was not universally available to patients 
in this study due to cost. The average cost of a two 
week dose of AMB in Kenya is approximately $88 or 
Kshs 500/50mg vial of AMB. At MDH patients waited 
for their families to procure AMB before treatment 
was initiated. Thus, treatment with AMB was either 
delayed, given partially or never administered. Efforts 
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to improve access to AMB in public hospitals in Kenya 
will be useful. 
 There were a number of limitations in this 
study. It is difficult to generalise our finding to the 
wider national population. However, our study 
sites are referral hospitals that admit patients from 
different regions of the country; thus reflecting the 
national situation. Patient follow-up was difficult. 
We did not confirm what diagnosis the CM negative 
patients in this study had. Our efforts concentrated 
on quantifying the prevalence of CM among these 
patients. We suspect that some of the patients may 
have had bacterial or viral meningitis. It will be 
interesting to determine the prevalence of other causes 
of meningitis among HIV patients in future studies. 
Most patients did not respond to our phone calls after 
they were discharged. We could not confirm mortality 
attributable to CM since our study did not include 
diagnostic tests that would confirm the presence 
of other opportunistic infections. Nevertheless, the 
study confirms the continued high prevalence of CM 
among HIV patients with suspected CM, and provides 
new information on excessively high in-hospital 
mortality of these patients despite the administration 
of FLC and AMB. It also identifies steps that can be 
taken to improve management and outcome of CM 
patients. 
In conclusion, the study reports a high prevalence 
of CM and CM-associated mortality among 
immunosuppressed HIV/AIDS patients at public 
hospitals in Kenya.  Even with the FLC donation 
programme greater treatment success is hampered 
by the inadequate capacity to manage CM and 
late presentation of patients with advanced CM. 
Developing a standard national guideline for 
CM management, improving access to AMB and 
expanding of laboratory capacity for diagnosing CM 
in public hospitals can help improve outcomes. 
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